Drug Trial Radar · NCT06052059
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,109
Actual
Start
Oct 25, 2023
Primary completion
Aug 12, 2026
Study completion Aug 1, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- PPD, Part of Thermo Fisher Scientific
- First posted
- Sep 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12.
Conditions
- Ulcerative Colitis
Interventions
IV TulisokibartDrug
Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
IV PlaceboDrug
Placebo matching IV tulisokibart
SC TulisokibartDrug
Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously
SC PlaceboDrug
Placebo matching SC tulisokibart
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study 1: Percentage of Participants Achieving Clinical Remission Per Modified Mayo Score (MMS) at Week 12Time frame: Week 12
- Study 1: Percentage of Participants Achieving Clinical Remission Per MMS at Week 52Time frame: Week 52
- Study 2: Percentage of Participants Achieving Clinical Remission Per MMS at Week 12Time frame: Week 12
Locations
476 sites in 45 countries. Site status is shown where the registry gives one.
Digestive Health Specialists ( Site 0135)
Dothan, Alabama
IMC-Gulf Coast Gastroenterology ( Site 0157)
Fairhope, Alabama
Research Solutions of Arizona ( Site 3816)
Litchfield Park, Arizona
One of a Kind Clinical Research Center ( Site 3852)
Scottsdale, Arizona
GI Alliance - Sun City ( Site 0103)
Sun City, Arizona
Clinnova Research ( Site 3803)
Anaheim, California
Southern California Research Center ( Site 3828)
Coronado, California
UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0113)
La Jolla, California
Cedars-Sinai Medical Center ( Site 0119)
Los Angeles, California
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3851)
Orange, California
University of Colorado Anschutz Medical Campus-Division of Gastroenterology and Hepatology ( Site 0172)
Aurora, Colorado
Peak Gastroenterology Associates ( Site 0116)
Colorado Springs, Colorado
South Denver Gastroenterology, PC ( Site 3849)
Englewood, Colorado
Rocky Mountain Gastroenterology/Topography Health ( Site 3838)
Littleton, Colorado
Connecticut Clinical Research Institute ( Site 0126)
Bristol, Connecticut
Medical Research Center of Connecticut ( Site 0151)
Hamden, Connecticut
Yale University School of Medicine-Digestive Disease ( Site 0163)
New Haven, Connecticut
Emerson Clinical Research Institute ( Site 3820)
Washington D.C., District of Columbia
Gastroenterology Consultants of Clearwater ( Site 0152)
Clearwater, Florida
University of Florida College of Medicine-Gastroenterology ( Site 3821)
Gainesville, Florida
Nature Coast Clinical Research - Inverness ( Site 3806)
Inverness, Florida
Central Florida Gastro Research ( Site 0124)
Kissimmee, Florida
Research Associates of South Florida - Miami - Southwest 8th Street ( Site 3810)
Miami, Florida
Orlando Health ( Site 0145)
Orlando, Florida
USF Health ( Site 0169)
Tampa, Florida
Emory University School of Medicine ( Site 3818)
Atlanta, Georgia
Atlanta Gastroenterology Associates - Peachtree Dunwoody ( Site 0115)
Atlanta, Georgia
Atlanta Center for Gastroenterology ( Site 0155)
Decatur, Georgia
University of Chicago Medical Center ( Site 0134)
Chicago, Illinois
GI Alliance - Glenview ( Site 0168)
Glenview, Illinois
GI ALLIANCE - GURNEE ( Site 0107)
Gurnee, Illinois
Iowa Digestive Disease Center ( Site 0123)
Clive, Iowa
University of Louisville Hospital-Clinical Trials Unit ( Site 0165)
Louisville, Kentucky
Baton Rouge General Medical Center - Bluebonnet ( Site 0112)
Baton Rouge, Louisiana
Tulane University School of Medicine-Gastroenterology and Hepatology ( Site 0154)
New Orleans, Louisiana
Walter Reed National Military Medical Center ( Site 0121)
Bethesda, Maryland
Woodholme Gastroenterology Associates-Woodholme Gastroenterology Associates ( Site 3835)
Glen Burnie, Maryland
Massachusetts General Hospital-Crohn's and Colitis Center ( Site 0132)
Boston, Massachusetts
University of Michigan ( Site 0143)
Ann Arbor, Michigan
Clinical Research Institute of Michigan, LLC ( Site 0108)
Clinton Township, Michigan
Showing 40 of 476 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.